HCA Healthcare, Inc.

▲ Bull Case

• ◆ACA subsidies renewed in H2 2026 → FY2027 guidance beats significantly: Congress extends enhanced ACA subsidies for 2027+; HCA's HIX headwind reverses by $400-600M in FY2027; management raises FY2027 guidance mid-year; stock re-rates from 15x to 20x FY2027E EPS; EPS $44 FY2028 × 21x = $924 (+97%)
• ◆Buyback compounding doubles EPS without heroic EBITDA growth: $10B FY2026 + $7B FY2027-2028 = 55M shares retired; share count falls from 239M to ~175M; combined with 7% EBITDA growth, EPS reaches $44 FY2028; buyback math alone (flat EBITDA) gets EPS to $36+ — entirely independent of regulatory outcome
• ◆Medicaid protection + deregulatory hospital M&A: Pro-business administration reduces FTC scrutiny of hospital consolidation; HCA acquires 2-3 hospital systems in Sun Belt for $2-3B total; tuck-in acquisitions add $300-500M EBITDA; combined with Medicaid protection = EBITDA reaches $20B by FY2028

▼ Bear Case

• ◆Medicaid per-capita caps enacted + HIX permanent headwind: House reconciliation passes with Medicaid per-capita cap; HCA estimates $800M-1.5B annual EBITDA reduction as states cut eligibility; simultaneously ACA subsidies expire permanently; combined $1.3-2.4B EBITDA headwind; EPS $28 FY2028 at 14x = $392 (-17%)
• ◆Site-neutral payment expansion by CMS: CMS issues final rule expanding site-neutral payments from specific procedures to all hospital outpatient services; HCA's HOPD pricing advantage vs. physician offices eliminated; $800M-1.2B annual revenue loss at full implementation; EBITDA margin compresses to 18-19%; EPS in mid-$20s
• ◆Volume disruption from elective deferral recession: Economic recession + high co-pays → patients defer elective procedures (orthopedics, cardiac, oncology); same-facility admissions -2-3%; combined with cost inflation; EBITDA margin compresses; EPS growth stalls at 2-4%/yr even with buybacks

“Is the HIX/ACA headwind truly transient (and thus creating a buying opportunity), or has the payer mix permanently shifted toward lower-acuity Medicaid/uninsured patients? Bull view: ACA subsidies have been extended every time threatened; politically popular in swing states. Even without renewal, HIX patients don't disappear — they shift to Medicaid (lower rate) or self-pay. HCA's collection rate and cost structure absorb this. Market prices a cliff, not a slope. Bear view: ACA exchange patient is a specific demographic (40-64, pre-Medicare). If subsidies expire, this cohort shifts coverage in ways that reduce commercial payer mix permanently. Medicaid rate increases don't fully compensate. Structural payer mix change is the real risk. Our view: Historical pattern of ACA subsidy extension is strong, supporting the bull. But bear's structural payer mix concern is worth taking seriously. At $470, bear case downside is only -17% while PWFV upside is +43%, creating a 2.5:1 risk/reward strongly favoring the bull.”

• ◆Q2 2026 (Jul): HIX headwind quantification vs. guidance; EBITDA tracking $16B midpoint = confidence
• ◆ACA subsidy renewal legislation (H2 2026 – Q1 2027); Subsidy renewal = major bull catalyst
• ◆CMS OPPS final rule (Nov 2026); Scope determines impact on HOPD pricing
• ◆Q3 2026 (Oct): Back-half EBITDA ramp confirmation; EBITDA $4.2B+ validates guidance
• ◆Medicaid reconciliation outcome (H2 2026); Determines structural EBITDA risk
• ◆New $10B buyback authorization (FY2026 annual meeting); Confirms capital allocation thesis
• ◆FY2027 initial guidance (Jan 2027); Guidance $34-36 validates buyback compounding model

• ◆Medicaid per-capita caps enacted (20% probability, High severity): $800M-1.5B annual EBITDA impairment; bipartisan opposition in expansion states provides buffer
• ◆ACA subsidies expire permanently (25% probability, Moderate severity): Enhanced subsidies extended twice; political stakes high in swing states; bear case models this scenario
• ◆CMS site-neutral payment expansion to >50% of HOPD services (25% probability, Moderate severity): HOPD pricing power permanently impaired; ASC buildout partially hedges; courts may limit scope
• ◆Recession-driven elective deferral (15% probability, Moderate severity): Same-facility admissions -2-3%; Sun Belt demographics provide volume floor; Medicare non-deferrable
• ◆CEO Hazen departure (10% probability, Low severity): Operational playbook is institutional; COO succession likely; modest downside risk
• ◆Debt/leverage at $47B net debt (20% probability, Moderate severity): Net Debt/EBITDA 3.0x (improving); all fixed-rate; investment-grade; conservative for hospital operator